Drug Trial Radar · NCT01769170
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
Last checked: Nov 19, 2026Latest source record: Jul 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
452
Actual
Start
Aug 2013
Primary completion
Dec 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- Jan 16, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of cytomegalovirus (CMV) infection in stem cell transplant patients who were CMV seropositive but negative for CMV viremia before starting treatment with BCV.
Conditions
- CMV
Interventions
BrincidofovirDrug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-TransplantTime frame: 24 weeks
Locations
43 sites in 3 countries. Site status is shown where the registry gives one.
University of California, San Diego-Moores Cancer Center
La Jolla, California
UCLA Medical Center
Los Angeles, California
University of Colorado
Denver, Colorado
Colorado Blood Cancer Institute
Denver, Colorado
University of Miami Hospital
Miami, Florida
Winship Cancer Institute-Emory
Atlanta, Georgia
Northside Hospital
Atlanta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
University of Chicago
Chicago, Illinois
The Universit of Iowa
Iowa City, Iowa
Johns Hopkins University
Baltimore, Maryland
Beth Isreal Decaconess Medical Center
Boston, Massachusetts
Brigham and Womens Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Harper University Hospital
Detroit, Michigan
Henry Ford Hospital
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Hackensack University
Hackensack, New Jersey
Mt. Sinai Medical Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Weill Cornell Medical College/NY Presbyterial Hospital
New York, New York
Montefiore Medical Center
The Bronx, New York
Levine Cancer Institute/Carolinas Health
Charlotte, North Carolina
Duke Cancer Institute
Durham, North Carolina
Wake Forest
Winston-Salem, North Carolina
Cincinnati Children's Hospital
Cincinnati, Ohio
The Jewish Hospital
Cincinnati, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Allegheny-Singer Research Institute
Pittsburgh, Pennsylvania
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
Hollings Cancer Center
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor University Medical Center
Dallas, Texas
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Methodist Healthcare of San Antonio
San Antonio, Texas
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah
Intermountain Healthcare
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
Cliniques Universitaires Saint Luc
Brussels, Belgium
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.